Pomerantz LLP and Levi & Korsinsky, LLP said they are investigating Teladoc Health, Inc. on behalf of investors after the company reported second-quarter 2026 results, cut its full-year 2026 revenue outlook to $2.36 billion to $2.45 billion, and its shares fell sharply. Teladoc reported Q2 2026 consolidated revenue of $606.9 million, below a cited consensus range of $615 million to $628 million. The company had previously guided to 2026 revenue of $2.47 billion to $2.59 billion on February 25, 2026, later updated to about $2.48 billion to $2.57 billion on April 29, 2026. Teladoc said the reduction reflected "uncertainties inherent in cash pay and ongoing business model transition," with BetterHelp facing faster insurance preference, an accelerated decline in cash-pay users, and insurance network capacity not expanding as quickly as demand. Pomerantz cited a 38.32% one-day decline on July 30, 2026, while the Levi & Korsinsky release described the shares as down more than 28% intraday after the results.